Education
About Us
Working with TipRanks
Follow Us
scPharmaceuticals Inc (SCPH)
NASDAQ:SCPH
SCPH Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.94 - $5.65
Previous CloseN/A
Volume61.66K
Average Volume (3M)640.94K
Market Cap
$129.73M
Enterprise Value$166.30M
Total Cash (Recent Filing)-$1.57M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.11
Next Earnings
May 20, 2025EPS Estimate
-0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.91
Shares Outstanding50,283,924
10 Day Avg. Volume642,217
30 Day Avg. Volume640,936
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)4.98
Price to Cash Flow (P/CF)-2.20
P/FCF Ratio0.00
Enterprise Value/Market Cap1.28
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit6.66
Enterprise Value/Ebitda-2.15
Forecast
1Y Price Target
$16.50Price Target Upside547.06% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
---
scPharmaceuticals News
PremiumCompany Announcements
scPharmaceuticals’ Earnings Call Highlights Growth and Challenges
PremiumCompany Announcements
scPharmaceuticals Reports Strong Revenue Growth in 2024---
Bulls Say, Bears Say
Bulls Say
FDA ApprovalFDA approval of the sNDA for Furoscix meaningfully expands its labeled indication to include edema in patients with chronic kidney disease (CKD), representing a significant positive milestone.
Market ExpansionThe expansion to CKD is a significant market opportunity and expands Furoscix’s prescriber base to nephrologists.
Sales GrowthManagement's various initiatives to accelerate Furoscix sales trajectory are now coming to fruition.
Bears Say
Cost ConcernsThe autoinjector submission remains on track and may reduce costs associated with Furoscix by approximately 70%.
Market CompetitionCKD patients represent a substantial portion of the potential market for Furoscix, and management has previously indicated strong interest from nephrologists who see value in an at-home treatment option like Furoscix for these patients.
Sales ForecastThe long-term peak sales forecast for Furoscix in heart failure and chronic kidney disease has been lowered to reflect a more measured uptake trajectory.
---
Ownership Overview
21.84% Insiders
7.38% Mutual Funds
0.10% Other Institutional Investors
63.69% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SCPH FAQ
What was scPharmaceuticals Inc’s price range in the past 12 months?
scPharmaceuticals Inc lowest stock price was $1.94 and its highest was $5.65 in the past 12 months.
What is scPharmaceuticals Inc’s market cap?
scPharmaceuticals Inc’s market cap is $129.73M.
When is scPharmaceuticals Inc’s upcoming earnings report date?
scPharmaceuticals Inc’s upcoming earnings report date is May 20, 2025 which is in 33 days.
How were scPharmaceuticals Inc’s earnings last quarter?
scPharmaceuticals Inc released its earnings results on Mar 19, 2025. The company reported -$0.35 earnings per share for the quarter, beating the consensus estimate of -$0.378 by $0.028.
Is scPharmaceuticals Inc overvalued?
According to Wall Street analysts scPharmaceuticals Inc’s price is currently Undervalued.
Does scPharmaceuticals Inc pay dividends?
scPharmaceuticals Inc does not currently pay dividends.
What is scPharmaceuticals Inc’s EPS estimate?
scPharmaceuticals Inc’s EPS estimate is -0.3.
How many shares outstanding does scPharmaceuticals Inc have?
scPharmaceuticals Inc has 50,283,924 shares outstanding.
What happened to scPharmaceuticals Inc’s price movement after its last earnings report?
scPharmaceuticals Inc reported an EPS of -$0.35 in its last earnings report, beating expectations of -$0.378. Following the earnings report the stock price went down -0.987%.
Which hedge fund is a major shareholder of scPharmaceuticals Inc?
Currently, no hedge funds are holding shares in SCPH
---
scPharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$16.50 (547.06% Upside)
$16.50 (547.06% Upside)
Blogger Sentiment
Bullish
SCPH Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 296.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 4.7%
Last 30 Days ▼ 4.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-45.57%
12-Months-Change
Fundamentals
Return on Equity
-336.97%
Trailing 12-Months
Asset Growth
13.80%
Trailing 12-Months
Company Description
scPharmaceuticals Inc
scPharmaceuticals Inc. (SCPH) is a biopharmaceutical company focused on the development and commercialization of transformative pharmaceutical products. The company's primary aim is to address unmet needs in the management of heart failure and infectious diseases. Its core product is FUROSCIX, a proprietary subcutaneous formulation of furosemide, which is designed to be a convenient self-administered treatment for heart failure patients who require diuretic therapy.
---
SCPH Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a positive sentiment overall, with strong revenue growth and strategic advancements like the FDA approval for CKD. However, increased operating expenses and a higher net loss pose challenges. The company is optimistic about future growth driven by Medicare redesign and product expansion.Read More>---
SCPH Stock 12 Month Forecast
Average Price Target
$16.50
▲(547.06% Upside)
Technical Analysis
Best Analysts Covering SCPH
1 Year
1 Year Success Rate
5/18 ratings generated profit
1 Year Average Return
-10.03%
reiterated a buy rating 29 days ago
Copying Douglas Tsao's trades and holding each position for 1 Year would result in 27.78% of your transactions generating a profit, with an average return of -10.03% per trade.
---